课题基金 / 基金详情

PHASE I STUDY OF CP 358,774 IN SUBJECTS W/ ADVANCED SOLID TUMORS

PHASE I STUDY OF CP 358,774 IN SUBJECTS W/ ADVANCED SOLID TUMORS
CP 358,774 在晚期实体瘤受试者中的 I 期研究
批准号：
6586828
负责人：
ERIC K ROWINSKY
金额：
$23.48万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
2001
资助国家：
美国
项目状态：
已结题
起止时间：
2001-12-01 至 2002-11-30
来源：
https://reporter.nih.gov/project-details/6586828
关键词：
antineoplastics clinical research clinical trial phase I dosage drug administration rate /duration drug adverse effect epidermal growth factor growth factor receptors human subject human therapy evaluation neoplasm /cancer chemotherapy neoplastic growth pharmacokinetics

项目摘要

项目成果

ERIC K ROWINSKY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is an open-label, dose and regimen escalation study of CP-358,774, a novel anti-cancer agent which inhibits epidermal growth factor receptor (EGFR) tyrosine kinase actvity and thus inhibits the growth of human EGFR-expressing tumors. The purpose of the study is to evluate the safety, toleration, pharmacokinetics and maximum tolerated dose of daily administration of CP-358,774 to patients with advanced cancers. A secondary objective of the study is to evaluate the anti-tumor activity of daily dosing of the study drug, using validated clinical endpoints. The study has three sequential treatment legs incorporating different frequencies of administration.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ph I Study Of BMS-247550 In PTS with advanced Neoplasms
Phase II Pharmacologic/Biologic Study of Thalidomide
Ph I Pharmacokinetics of NSC-655649/Cisplatin/G-CSF
PHASE I TRIAL OF LY231514 IN PATIENTS W/ VARYING DEGREES OF RENAL FUNCTION
海外基金